Literature DB >> 9763402

Biodistribution and clearance of 125I-labeled C-reactive protein and 125I-labeled modified C-reactive protein in CD-1 mice.

M Motie1, K W Schaul, L A Potempa.   

Abstract

Iodinated forms of C-reactive protein (CRP), soluble modified CRP (mCRP-sol), and suspended mCRP (mCRP-susp) were injected iv into CD-1 mice, for analysis of their pharmacokinetics (PK) and biodistribution (BD). The plasma half-life of 125I-CRP, measured as 4.7 hr, agrees closely with previous reports. The PK and BD characteristics for 125I-mCRP-sol and 125I-mCRP-susp were comparable to each other and were distinctly different from those measured for CRP. Whereas approximately 50% of 125I-CRP was recoverable from plasma 5 min after injection, only approximately 5% of 125I-mCRP was similarly recoverable. The estimated volume of distribution at steady state calculated for either form of 125I-mCRP was approximately 10-fold greater than that calculated for 125I-CRP (23. 4-27.6 and 2.4 ml, respectively). The estimated mean residence times for 125I-mCRP were approximately 2 times longer than that measured for 125I-CRP (9.5-11.5 hr, compared with 4.9 hr). At both 4- and 24-hr time points, substantial amounts of 125I-mCRP were selectively distributed in the bone marrow. At 24 hr, approximately 25% of the injected 125I-mCRP-sol and 125I-mCRP-susp was localized to the bone marrow (corresponding to 92% of injected dose/g of tissue). At this time point, only 8% (or 27%/g) of 125I-CRP was localized to the bone marrow. Overall, the data presented indicate that 1) mCRP has PK and BD characteristics distinct from those of CRP; 2) injected mCRP, although it is rapidly cleared from the general circulation, accesses large body areas and is selectively localized to the bone marrow; and 3) all forms of CRP appear to be excreted in the urine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9763402

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  13 in total

1.  Change in cardiovascular risk factors with progression of kidney disease.

Authors:  Linda F Fried; Ronit Katz; Mary Cushman; Mark Sarnak; Michael G Shlipak; Lewis Kuller; Anne B Newman
Journal:  Am J Nephrol       Date:  2008-10-24       Impact factor: 3.754

2.  Binding of the monomeric form of C-reactive protein to enzymatically-modified low-density lipoprotein: effects of phosphoethanolamine.

Authors:  Sanjay K Singh; Madathilparambil V Suresh; David J Hammond; Antonio E Rusiñol; Lawrence A Potempa; Alok Agrawal
Journal:  Clin Chim Acta       Date:  2009-06-21       Impact factor: 3.786

3.  Comparison of succinimidyl [(125)I]iodobenzoate with iodogen iodination methods to study pharmacokinetics and ADME of biotherapeutics.

Authors:  Jianqing Chen; Mengmeng Wang; Alison Joyce; David DeFranco; Mania Kavosi; Xin Xu; Denise M O'Hara
Journal:  Pharm Res       Date:  2014-05-21       Impact factor: 4.200

4.  Topological localization of monomeric C-reactive protein determines proinflammatory endothelial cell responses.

Authors:  Hai-Yun Li; Jing Wang; Yue-Xin Wu; Lin Zhang; Zu-Pei Liu; János G Filep; Lawrence A Potempa; Yi Wu; Shang-Rong Ji
Journal:  J Biol Chem       Date:  2014-04-07       Impact factor: 5.157

5.  C-reactive protein protects mice against pneumococcal infection via both phosphocholine-dependent and phosphocholine-independent mechanisms.

Authors:  Toh B Gang; Gregory A Hanley; Alok Agrawal
Journal:  Infect Immun       Date:  2015-02-17       Impact factor: 3.441

Review 6.  The protective function of human C-reactive protein in mouse models of Streptococcus pneumoniae infection.

Authors:  Alok Agrawal; Madathilparambil V Suresh; Sanjay K Singh; Donald A Ferguson
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2008-12       Impact factor: 2.895

7.  Binding of C-reactive protein to modified low-density-lipoprotein particles: identification of cholesterol as a novel ligand for C-reactive protein.

Authors:  Sanna Taskinen; Petri T Kovanen; Hanna Jarva; Seppo Meri; Markku O Pentikäinen
Journal:  Biochem J       Date:  2002-10-15       Impact factor: 3.857

Review 8.  The connection between C-reactive protein and atherosclerosis.

Authors:  Sanjay K Singh; Madathilparambil V Suresh; Bhavya Voleti; Alok Agrawal
Journal:  Ann Med       Date:  2008       Impact factor: 4.709

9.  Role of the property of C-reactive protein to activate the classical pathway of complement in protecting mice from pneumococcal infection.

Authors:  Madathilparambil V Suresh; Sanjay K Singh; Donald A Ferguson; Alok Agrawal
Journal:  J Immunol       Date:  2006-04-01       Impact factor: 5.422

10.  C-reactive protein-bound enzymatically modified low-density lipoprotein does not transform macrophages into foam cells.

Authors:  Sanjay K Singh; Madathilparambil V Suresh; Deborah C Prayther; Jonathan P Moorman; Antonio E Rusiñol; Alok Agrawal
Journal:  J Immunol       Date:  2008-03-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.